Skip to content
    Roche Venture Fund logo

    Roche Venture Fund

    Basel, SwitzerlandFounded 2002
    www.roche.com/venturefundLinkedIn
    Biotech & Life SciencesHealthcare

    The Roche Venture Fund is the corporate venture fund of Roche, a global leader in pharmaceuticals and diagnostics. It invests in early-stage innovative life science companies across pharmaceuticals, diagnostics, and digital health, aiming to develop commercially successful companies while generating financial returns for Roche.

    46% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $57.9M (across 68 rounds with reported amounts).

    Find people at Roche Venture Fund on Goldilocks AI

    Portfolio

    62

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    3

    Team

    BF

    Bryan Faust

    Investment Director

    MS

    Monique Schiersing

    Senior Investment Director

    SG

    Simon Greenwood

    Senior Investment Director

    AH

    Anja Harmeier

    Head Roche Venture Fund

    Dr Aviv Regev*

    Dr Aviv Regev*

    Head of Genentech Research and Early Development (gRED)

    Prof. Dr Mark Dawson*

    Prof. Dr Mark Dawson*

    Head of Roche Pharma Research and Early Development (pRED)

    Boris L. Zaïtra*

    Boris L. Zaïtra*

    Head of Corporate Business Development

    Claudia Böckstiegel*

    Claudia Böckstiegel*

    General Counsel

    Cristina A. Wilbur

    Cristina A. Wilbur

    Chief People Officer

    Dr Alan Hippe

    Dr Alan Hippe

    Chief Financial Officer

    Dr Levi Garraway*

    Dr Levi Garraway*

    Head of Global Product Development and Chief Medical Officer

    Dr Nina Schwab-Hautzinger*

    Dr Nina Schwab-Hautzinger*

    Head of Group Communications

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    106 investments
    CompanyRoundAmountDate
    Mironid logoMironidSeries B$46MAug 2026
    CCour PharmaSeries B$50MJun 2026
    CCour PharmaSeries B$50MJan 2026
    Mission Therapeutics logoMission TherapeuticsUnknown$13.3MOct 2025
    SpliceBio logoSpliceBioSeries B$135MJun 2025
    SSplice BioSeries B$135MJun 2025
    GlycoEra logoGlycoEraSeries B$130MMay 2025
    Freenome logoFreenomeGrowth$254MFeb 2024
    CCour PharmaSeries A$105MJan 2024
    GlycoEra logoGlycoEraSeries A—Jan 2024
    Forcefield Therapeutics logoForcefield TherapeuticsSeries A—Jan 2024
    NMD Pharma logoNMD PharmaSeries B—Nov 2023
    DiogenX logoDiogenXSeries A$33.5MOct 2023
    Mironid logoMironidSeries A—Sep 2023
    DiogenX logoDiogenXSeries A—Jan 2023
    XUND logoXUNDSeed—Sep 2022
    NMD Pharma logoNMD PharmaUnknown—Feb 2022
    Forcefield Therapeutics logoForcefield TherapeuticsUnknown—Jan 2022
    Good Therapeutics logoGood TherapeuticsSeries B$8MDec 2021
    GlycoEra logoGlycoEraSeries A—Oct 2021
    SSoteria BiotherapeuticsSeries A$42MMay 2021
    Arch Oncology, Inc. logoArch Oncology, Inc.Series C$105MApr 2021
    Entrada Therapeutics logoEntrada TherapeuticsSeries B$116MMar 2021
    Kumquat Biosciences logoKumquat BiosciencesUnknown$70MJan 2021
    Entrada logoEntradaSeries B$116MJan 2021
    Page 1 of 5

    Top Co-Investors

    Novartis Venture Fund13 shared
    Sofinnova Partners11 shared
    SR One10 shared
    Pfizer Ventures10 shared
    RA Capital Management9 shared
    Ysios Capital9 shared
    Amgen Ventures8 shared
    GV7 shared
    Perceptive Advisors7 shared
    MRL Ventures Fund7 shared
    New Enterprise Associates6 shared
    Versant Ventures6 shared
    Alexandria Venture Investments6 shared
    Polaris Partners6 shared
    Kurma Partners6 shared
    Omnes Capital6 shared
    Cormorant Asset Management6 shared
    Agent Capital6 shared
    MPM Capital6 shared
    Qatar Investment Authority6 shared

    Last updated: 20 October 2026